Street:Banjara Hills, Hyderabad - 500034, Andhra Pradesh - INDIA
MaxCard:
About us
Welcome To Our Site!
Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company.
As a fully integrated pharmaceutical company, our purpose is to provide affordable and innovative medicines through our three core businesses: Pharmaceutical Services and Active Ingredients, comprising our Active Pharmaceuticals and Custom Pharmaceuticals businesses; Global Generics, which includes branded and unbranded generics; and Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated Formulations, and Generic Biopharmaceuticals. Our products are marketed globally, with a focus on India, US, Europe and Russia. Dr. Reddy’s conducts NCE research in the areas of metabolic disorders, cardiovascular indications, anti-infectives and inflammation.
Our strong portfolio of businesses, geographies and products gives us an edge in an increasingly competitive global market and allows us to provide affordable medication to people across the world, regardless of geographic and socio-economic barriers. Founded in 1984 by entrepreneur scientist Dr. K Anji Reddy Our Purpose: Providing Affordable and Innovative medicines for healthier lives Our Offerings: Over 40 product families marketed in the US 133 ANDAs filled till date. 69 ANDAs pending approval at the USFDA, of which 32 are Para IV and 19 are FTFs About 160 products marketed in the EU 200+ branded formulations marketed in the Rest of the world markets Product Portfolio: Generics Active Pharma Ingredients Custom Pharma Solutions Branded and Unbranded Generics NCEsDifferentiated formulations Product Portfolio: Active Pharmaceutical Ingredients (APIs) Among the Top-3 API player globally 140 APIs in the market 20 products under development at any given point of time Product Portfolio: Proprietary Products Generic Biopharmaceuticals 2 products in the market: GrafeelTM (generic Filgrastim) & RedituxTM, (generic Rituximab) 8 products in pipeline Branded and Unbranded Generics Promius Pharma2 products in the market: EpiCeram? Skin Barrier Emulsion and Scytera? Foam Infrastructure: PSAI: 8 USFDA inspected facilities(6 in India, 1 in Mexico and 1 in UK); 3 Technology Development centers (2 in India and 1 in UK) One biologics development center One Integrated Product Development facility First manufacturing company from India to be SOX certified Our businesses employs about 11000 associates globally Among the top 12 generic companies in the US Rank 5th in Germany 7th largest Generic Pharma company in Russia Among the largest pharmaceutical companies in India We are the first Asia Pacific pharmaceutical company, outside Japan, to list on the New York Stock Exchange. We are the fastest Indian Pharma company to cross $1 billion in revenues. Acquired betapharm It was the largest overseas acquisition ever by an Indian company at that point of time.
India
